

**ondine**



**For Immediate Release**

**Ondine Announces Positive Clinical Results from its Periowave™ Trial of Maintenance Therapy**

**Vancouver, Canada – January 22, 2007** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that the publication of three Periowave™ clinical trial abstracts will be presented at the combined meetings of the International Association for Dental Research (IADR) and the American Association for Dental Research (AADR) meeting in New Orleans, March 21-24, 2007. The IADR/AADR meeting is expected to attract 5000 dental researchers from around the world who are dedicated to the prevention and treatment of oral and dental diseases.

Data to be published summarize results from a clinical trial of Ondine's Periowave™ photo disinfection technology for treatment of periodontal diseases. This trial was carried out in collaboration with the Loma Linda University School of Dentistry, Center for Dental Research, in Loma Linda, California. The trial was designed to evaluate the benefits of Periowave™ as a maintenance therapy in patients with moderate to severe chronic adult periodontitis.

“Results of this blinded, randomized, controlled study showed outstanding clinical efficacy with no related adverse effects”, stated Mr. David Hammond, Director of Clinical Affairs, Ondine Biopharma Corporation. “75% of the patients enrolled in the Periowave™ treatment arm showed greater than 2 millimeter reduction in pocket depth, compared to 20% of the subjects in the scaling and root planing (SRP) arm. A decrease of 2 millimeters or more in pocket depth is of tremendous benefit to a patient's treatment plan, particularly when this is achieved non-surgically rather than surgically. This three-fold increase clearly demonstrates the benefits of maintenance Periowave™ therapy in patients with moderate to severe disease.”

**About Periowave™ and Photodynamic Disinfection**

Periowave™ is a Photodynamic Disinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodynamic Disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com)

## **About Periodontal Disease**

Periodontitis (gum disease) is a common human affliction, affecting one third of all adults, and over half of the population over the age of 50. Periodontitis results in gum tissue detachment, bleeding gums, oral malodour, bone and tooth loss as well as other complications. The standard of care for treating periodontal disease is Scaling and Root Planing ("SRP"), or gum surgery, or both. SRP is the sub-gingival removal of plaque biofilm adhering to the root surfaces. Periodontitis is associated with a host of other serious conditions including heart disease, stroke, premature births and diabetes.

## **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodynamic Disinfection (PDD) provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine has developed Periowave™ for the treatment of chronic periodontitis in adults, and is extending its platform technology into other applications both within and outside the oral cavity. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com)

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

*The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release*

### **FOR FURTHER INFORMATION please contact:**

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
<a href="mailto:ccross@ondinebiopharma.com">ccross@ondinebiopharma.com</a>	<a href="mailto:cbessant@equicomgroup.com">cbessant@equicomgroup.com</a>